O	0	11	Multicenter
O	12	22	randomized
O	23	28	phase
O	29	32	III
O	33	38	study
O	39	41	of
O	42	45	the
O	46	62	cardioprotective
O	63	69	effect
O	70	72	of
B-intervention	73	84	dexrazoxane
I-intervention	85	86	(
I-intervention	86	96	Cardioxane
I-intervention	96	97	)
O	98	100	in
O	101	109	advanced
O	109	110	/
O	110	120	metastatic
O	121	127	breast
O	128	134	cancer
O	135	143	patients
O	144	151	treated
O	152	156	with
O	157	170	anthracycline
O	170	171	-
O	171	176	based
O	177	189	chemotherapy
O	189	190	.

B-condition	191	204	Anthracycline
I-condition	204	205	-
I-condition	205	212	induced
I-condition	213	227	cardiotoxicity
O	228	231	has
O	232	235	led
O	236	238	to
O	239	242	the
O	243	251	adoption
O	252	254	of
O	255	264	empirical
O	265	269	dose
O	270	276	limits
O	277	281	that
O	282	285	may
O	286	294	restrict
O	295	304	continued
O	305	308	use
O	309	311	of
O	312	326	anthracyclines
O	327	332	among
O	333	341	patients
O	342	345	who
O	346	351	might
O	352	359	benefit
O	359	360	.

O	361	372	Dexrazoxane
O	372	373	,
O	374	375	a
O	376	392	cardioprotective
O	393	398	agent
O	398	399	,
O	400	403	has
O	404	408	been
O	409	414	shown
O	415	417	to
O	418	424	reduce
O	425	428	the
O	429	433	risk
O	434	436	of
O	437	450	anthracycline
O	450	451	-
O	451	461	associated
O	462	476	cardiotoxicity
O	477	481	when
O	482	487	given
O	488	492	from
O	493	498	first
O	499	503	dose
O	504	506	of
O	507	520	anthracycline
O	520	521	.

O	522	526	This
O	527	532	study
O	533	539	sought
O	540	542	to
O	543	550	confirm
O	551	554	the
O	555	562	benefit
O	563	565	of
O	566	577	dexrazoxane
O	578	580	in
O	581	589	patients
O	590	592	at
O	593	597	high
O	598	602	risk
O	603	605	of
O	606	620	cardiotoxicity
O	621	624	due
O	625	627	to
O	628	633	prior
O	634	647	anthracycline
O	648	651	use
O	651	652	.

O	653	654	A
O	655	660	total
O	661	663	of
B-total-participants	664	667	164
B-eligibility	668	674	female
I-eligibility	675	681	breast
I-eligibility	682	688	cancer
I-eligibility	689	697	patients
I-eligibility	697	698	,
I-eligibility	699	709	previously
I-eligibility	710	717	treated
I-eligibility	718	722	with
I-eligibility	723	737	anthracyclines
O	737	738	,
O	739	747	received
O	748	761	anthracycline
O	761	762	-
O	762	767	based
O	768	780	chemotherapy
O	781	787	either
O	788	792	with
O	793	794	(
O	794	795	n
O	796	797	=
B-intervention-participants	798	800	85
O	800	801	)
O	802	804	or
B-control	805	812	without
O	813	814	(
O	814	815	n
O	816	817	=
B-control-participants	818	820	79
O	820	821	)
O	822	833	dexrazoxane
O	834	837	for
O	838	839	a
O	840	847	maximum
O	848	850	of
O	851	854	six
O	855	861	cycles
O	861	862	.

O	863	871	Compared
O	872	876	with
O	877	882	those
O	883	892	receiving
O	893	906	anthracycline
O	907	912	alone
O	912	913	,
O	914	922	patients
O	923	930	treated
O	931	935	with
O	936	947	dexrazoxane
O	948	959	experienced
O	960	973	significantly
O	974	979	fewer
B-outcome	980	987	cardiac
I-outcome	988	994	events
O	995	996	(
B-cv-bin-percent	996	998	39
I-cv-bin-percent	998	999	%
O	1000	1006	versus
B-iv-bin-percent	1007	1009	13
I-iv-bin-percent	1009	1010	%
O	1010	1011	,
O	1012	1013	P
O	1014	1015	<
O	1016	1017	0
O	1017	1018	.
O	1018	1021	001
O	1021	1022	)
O	1023	1026	and
O	1027	1028	a
O	1029	1034	lower
O	1035	1038	and
O	1039	1043	less
B-outcome	1044	1050	severe
I-outcome	1051	1060	incidence
I-outcome	1061	1063	of
I-outcome	1064	1074	congestive
I-outcome	1075	1080	heart
I-outcome	1081	1088	failure
O	1089	1090	(
B-cv-bin-percent	1090	1092	11
I-cv-bin-percent	1092	1093	%
O	1094	1100	versus
B-iv-bin-percent	1101	1102	1
I-iv-bin-percent	1102	1103	%
O	1103	1104	,
O	1105	1106	P
O	1107	1108	<
O	1109	1110	0
O	1110	1111	.
O	1111	1113	05
O	1113	1114	)
O	1114	1115	.

B-outcome	1116	1121	Tumor
I-outcome	1122	1130	response
I-outcome	1131	1135	rate
O	1136	1139	was
O	1140	1150	unaffected
O	1151	1153	by
O	1154	1165	dexrazoxane
O	1166	1173	therapy
O	1173	1174	.

O	1175	1178	The
B-outcome	1179	1188	frequency
I-outcome	1189	1191	of
I-outcome	1192	1199	adverse
I-outcome	1200	1206	events
O	1207	1210	was
O	1211	1218	similar
O	1219	1226	between
O	1227	1233	groups
O	1234	1237	and
O	1238	1243	there
O	1244	1248	were
O	1249	1251	no
O	1252	1263	significant
O	1264	1271	between
O	1271	1272	-
O	1272	1277	group
O	1278	1289	differences
O	1290	1292	in
O	1293	1296	the
B-outcome	1297	1303	number
I-outcome	1304	1306	of
I-outcome	1307	1311	dose
I-outcome	1312	1325	modifications
I-outcome	1325	1326	/
I-outcome	1326	1339	interruptions
O	1339	1340	.

O	1341	1352	Dexrazoxane
O	1353	1366	significantly
O	1367	1374	reduced
O	1375	1378	the
O	1379	1389	occurrence
O	1390	1393	and
O	1394	1402	severity
O	1403	1405	of
O	1406	1419	anthracycline
O	1419	1420	-
O	1420	1427	induced
O	1428	1442	cardiotoxicity
O	1443	1445	in
O	1446	1454	patients
O	1455	1457	at
O	1458	1467	increased
O	1468	1472	risk
O	1473	1475	of
O	1476	1483	cardiac
O	1484	1495	dysfunction
O	1496	1499	due
O	1500	1502	to
O	1503	1511	previous
O	1512	1525	anthracycline
O	1526	1535	treatment
O	1536	1543	without
O	1544	1556	compromising
O	1557	1560	the
O	1561	1570	antitumor
O	1571	1579	efficacy
O	1580	1582	of
O	1583	1586	the
O	1587	1603	chemotherapeutic
O	1604	1611	regimen
O	1611	1612	.
